biostudies-literatureUnknown2023Jianfang F<h4>Objective</h4>The aim of study was to evaluate the effect and safety of pioglitazone-metformin combined treatment in the newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease.<h4>Methods</h4>A total of 120 newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease from 8 centers were randomly divided into the control group (metformin hydrochloride) and the test group (pioglitazone hydrochloride and metformin hydrochloride).<h4>Results</h4>Compared to the control group, after treatment, the proportion of people with mild and moderate fatty liver increased, and the proportion of people with severe fatty liver decreased, and this change was more obvious in the population with moderate and severe fatty liver. The level of <i>γ</i>-GT decreased iJournal of diabetes research2044090https://www.ebi.ac.uk/biostudies/studies/S-EPMC10250100biostudies-literatureEffect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.PMC10250100Jianfang FQiuhe JWanxia XMengying LJianrong LQian XJing XXiling GTaixiong CWenjuan YJie MKaiyan MQingzhen HJingxuan LfalseEffect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.<h4>Objective</h4>The aim of study was to evaluate the effect and safety of pioglitazone-metformin combined treatment in the newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease.<h4>Methods</h4>A total of 120 newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease from 8 centers were randomly divided into the control group (metformin hydrochloride) and the test group (pioglitazone hydrochloride and metformin hydrochloride).<h4>Results</h4>Compared to the control group, after treatment, the proportion of people with mild and moderate fatty liver increased, and the proportion of people with severe fatty liver decreased, and this change was more obvious in the population with moderate and severe fatty liver. The level of <i>γ</i>-GT decreased i2023-01-01T00:00:00Z20232025-04-21T23:51:48.67Z2024-11-15T07:21:29.796ZS-EPMC102501003730542910.1155/2023/2044090